Shows / GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News
One GLP-1 story a day, sourced and explained. GLP-1 Newspaper covers the biggest daily news on weight-loss and diabetes drugs like Ozempic, Wegovy, Zepbound, Mounjaro, and new ones like retatrutide, orforglipron, and the Wegovy pill. Each short episode breaks down one story, such as an FDA decision, new trial results, price and insurance changes, shortages, or safety updates. We cover what happened, what it means for patients, and what we don't know yet. Every episode links to its primary…
Episodes
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsLilly's Retatrutide Beat Ozempic 2 mg on Blood Sugar and Weight Loss in Head-to-Head Diabetes Trial
Eli Lilly says its investigational once-weekly drug retatrutide beat Novo Nordisk's Ozempic 2 mg in TRANSCEND-T2D-2, the first Phase 3 trial comparing…
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsLilly Registers Two Phase 3 Trials of EloraTZP, Its Eloralintide-Tirzepatide Combination
Eli Lilly has registered two phase 3 trials of EloraTZP, an investigational once-weekly combination of the amylin agonist eloralintide and tirzepatide (the…
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsLilly's Retatrutide Eased Sleep Apnea in Two Phase 3 Trials, NEJM Study Reports
Two phase 3 trials published in the New England Journal of Medicine found that Eli Lilly's investigational drug retatrutide, a once-weekly injection that acts…
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsACOG Issues New Guidance on GLP-1 Drugs Before Pregnancy, During Pregnancy and While Breastfeeding
The American College of Obstetricians and Gynecologists (ACOG) released new guidance on October 23, 2026, on GLP-1 medications before, during and after…
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsCompounded GLP-1 Recall and 'Research Use' Retatrutide Put Unapproved Weight-Loss Drugs Under Scrutiny
Unapproved GLP-1 drugs are under pressure from several directions. Compounding pharmacy Apothecary Pharma voluntarily recalled 22 lots of compounded…
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsEU Regulators Back Lilly's Foundayo Pill for Weight Loss and Type 2 Diabetes
Europe's drug regulator has recommended approval of Eli Lilly's once-daily GLP-1 pill Foundayo (orforglipron) for adults, covering both weight management and…
GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug NewsNovo Says Women Lost 25% on CagriSema in Trial Analysis, With Differences by Menopause Stage
Novo Nordisk says women in its phase 3 REDEFINE 1 trial lost 25.0% of their body weight on average after 68 weeks on its investigational weekly injection…